PUBLIC COMPANY
save$BTAIBioXcel Therapeutics, Inc.
$BTAI0.9215-10.53%New Haven, CT, USupdated 2mo ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
3
approvals ytd
1
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
- phase1Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
- phase3Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
- phase1Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
- phase2Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
- phase4Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
- phase2A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
- phase3Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
🐶 Hiring Signal
News
- Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolioBioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.fiercebiotech · 1mo ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that